Oppenheimer initiates coverage on Eupraxia with Outperform rating
Oppenheimer analyst Jay Olson initiated coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17, indicating a positive outlook for the NASDAQ-listed stock.
*this image is generated using AI for illustrative purposes only.
Oppenheimer analyst Jay Olson has initiated coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17. The rating reflects a positive outlook on the company's performance potential.
Analyst Details
The coverage initiation was led by Jay Olson, an analyst at Oppenheimer. The Outperform rating suggests the stock is expected to perform better than the market average.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Price Target | $17 |
| Exchange | NASDAQ |
Eupraxia Pharmaceuticals is listed on NASDAQ under the ticker symbol EPRX.
What upcoming clinical milestones could drive Eupraxia Pharmaceuticals' stock price toward the $17 target?
How might the broader market conditions for biotech stocks influence Eupraxia's performance in the near term?
What competitive advantages does Eupraxia have over its peers in the pharmaceutical sector?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
